Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

on for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

                          IDENIX PHARMACEUTICALS, INC.

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                     (IN THOUSANDS, EXCEPT PER SHARE DATA)

                                   (UNAUDITED)

                                     Three Months Ended      Years Ended
                                         December 31,        December 31,
                                       2008      2007      2008       2007
    Revenues:
      Collaboration revenue -
       related party                 $4,247   $12,573    $9,815    $64,751
      Other revenue                      21        29       234      3,277
        Total revenues                4,268    12,602    10,049     68,028

    Operating expenses (1):
      Cost of sales                     479     1,487     1,745      2,001
      Research and development       11,949    20,294    53,887     85,839
      Selling, general and
       administrative                 5,702     9,278    27,130     63,348
      Restructuring and
    
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 ... an LC/MS amino acid analysis system developed jointly ... the UF-Amino Station can analyze 38 amino acids ... The UF-Amino Station achieves high-speed analysis utilizing a ... The LCMS-2020 provides accurate analytical results even under ...
(Date:7/23/2014)... 2014 StemGenex® , the leading ... US aimed at improving the lives of patients dealing ... for Parkinson’s disease. StemGenex believes that a commitment ... are paramount when providing care to patients with degenerative ... cell therapy accessible to the millions of individuals currently ...
(Date:7/23/2014)... 23, 2014 regulated information -- UCB today announced ... pipeline with positive topline results from the latest ... was designed to evaluate the efficacy and safety ... without titration) compared to placebo, as adjunctive treatment ... not fully controlled despite treatment with one or ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Mass., Oct. 10 Targanta,Therapeutics Corporation (Nasdaq: TARG ... of 5,750,000 shares of its common stock at a ... the shares are being offered by,Targanta. Targanta has granted ... an additional 862,500 shares of common stock at the ...
... Signalife has received,additional sales orders in excess of ... Lowell Harmison,s most recent cross-country sales,initiative. These purchase orders ... the company anticipates achieving break-even status,by the end of ... of 2008 first,quarter. About Signalife: Signalife, Inc. ...
... 10 DermTech International, Inc.,a biotechnology company ... of melanoma and other diseases, today appointed ... Board. Dr. Quackenbush is a,Professor of Biostatistics ... and Professor of Computational Biology and Bioinformatics,at ...
Cached Biology Technology:Targanta Therapeutics Announces Pricing of its Initial Public Offering 2Signalife Continues to Procure Purchase Orders, Revenues 2DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2
(Date:7/24/2014)... gut that has gone undetected by scientists for decades. ... State University has found that more than half the ... named crAssphage, which infects one of the most common ... of bacteria is thought to be connected with obesity, ... in Nature Communications ., Robert A. Edwards, a ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... of Defense recently awarded the STEMPREP Project at ... support its goal of increasing the number of ... minority middle school students for the two-summer classroom ... school students with summer opportunities at research labs. ... Simmons School of Education and Human Development, boasts ...
Breaking Biology News(10 mins):Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... NY, June 27, 2011Sophisticated genetic tools and techniques for ... in bone marrow will drive the successful application of ... Examples of these cutting-edge methods are presented in a ... of Human Gene Therapy , a peer-reviewed journal ...
... A team of researchers from the National Institute ... and the University of Maryland has made nano-sized ... from paints, cleaners, pesticides and other productsthat offer ... low-power room-temperature operation and the ability to detect ...
... Most previous studies have indicated that people in cities have ... country. By using more complex methods of analysis than in ... that people,s carbon emissions are practically the same in the ... CO 2 emissions that cause climate change are dependent ...
Cached Biology News:The promise of stem cell-based gene therapy 2Nanowire-based sensors offer improved detection of volatile organic compounds 2City dwellers produce as much CO2 as countryside people do 2
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... to ThPok ( Abpromise for all tested ... conjugated to KLH derived from within residues 500 ... the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: